Interferon-α may exacerbate cryoglobulinemia-related ischemic manifestations: An adverse effect potentially related to its anti-angiogenic activity

Arthritis and Rheumatism

Volumn 42, Issue 5, 1999, Pages 1051-1055

  Cid, Maria C ^a,c   Hernández Rodríguez, José ^a   Robert, Jordi ^a   Del Río, Ana ^a   Casademont, Jordi ^a   Coll Vinent, Blanca ^a   Grau, Josep M ^a   Kleinman, Hynda K ^b   Urbano Márquez, Alvaro ^a   Cardellach, Francesc ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; IMMUNOSUPPRESSIVE AGENT; PREDNISONE;

ADULT; ARTICLE; CASE REPORT; CRYOGLOBULINEMIA; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER FUNCTION; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

CRYOGLOBULINEMIA; HEPATITIS ANTIBODIES; HEPATITIS C; HUMANS; INTERFERON-ALPHA; ISCHEMIA; MALE; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 0345517249     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199905)42:5<1051::AID-ANR26>3.0.CO;2-Q     Document Type: Article

References (15)

1. Gorevic PD, Kassab HJ, Levo Y, Kohn R, Meltzer M, Prose P, et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 1980;69:287-308.
2. Agnello V, Romain PL. Mixed cryoglobulinemia secondary to hepatitis C virus infection. Rheum Dis Clin North Am 1996;22:1-21.
3. Misiani R, Bellavita P, Fenili D, Vicari O, Marchesi D, Sironi PL, et al. Interferon-α therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994;330:751-6.
4. Casato M, Laganà B, Antonelli G, Dianzani F, Bonomo L. Long-term results of therapy with interferon-α for type II essential mixed cryoglobulinemia. Blood 1991;78:3142-7.
5. La Civita L, Zignego AL, Lombardini F, Monti M, Longombardo G, Pasero G, et al. Exacerbation of peripheral neuropathy during alpha-interferon therapy in a patient with mixed cryoglobulinemia and hepatitis B virus infection. J Rheumatol 1996;23:1641-3.
6. Tada H, Saitoh S, Nakagawa Y, Hirana H, Morimoto M, Shima T, et al. Ischemic colitis during interferon-alpha treatment for chronic active hepatitis C. J Gastroenterol 1996;31:582-4.
7. Tilg H. New insights into the mechanisms of interferon alpha: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 1997;112:1017-21.
8. Wang J, Lin Q, Langston H, Cooper MD. Resident bone marrow macrophages produce type 1 interferons that can selectively inhibit interleukin-7-driven growth of B lineage cells. Immunity 1995;3: 475-84.
9. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor and lymphocyte-induced vascular responses. Cancer Res 1987;47:5155-61.
10. Stout AJ, Gresser I, Thompson WD. Inhibition of wound healing in mice by local interferon α/β injection. Int J Exp Pathol 1993;74:79-85.
11. Singh RK, Gutman M, Bucana CD, Sánchez R, Llansa N, Fidler JJ. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci U S A 1995;92:4562-6.
12. Ezekowitz AB, Mulliken JB, Folkman J. Interferon alpha-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992;326:1456-63.
13. Costa da Cunha CS, Lebbe C, Rybojad M, Agbalika F, Ferchal F, Rabian C, et al. Long-term follow-up of non-HIV Kaposi's sarcoma treated with low-dose recombinant interferon alpha-2b. Arch Dermatol 1996;132:327-31.
14. Coll-Vinent B, Cebrián M, Cid MC, Font C, Esparza J, Juan M, et al. Dynamic pattern of endothelial cell adhesion molecule expression in muscle and perineural vessels from patients with classic polyarteritis nodosa. Arthritis Rheum 1998;41:435-44.
15. Cid MC. New developments in the pathogenesis of systemic vasculitis. Curr Opin Rheumatol 1996;8:1-11.